Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析

◆英語タイトル:Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1331
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ultragenyx Pharmaceutical Inc (RARE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ultragenyx Pharmaceutical Inc (Ultragenyx) develops novel therapeutics for rare and ultra-rare genetic diseases. It has two marketed products, Mepsevii (vestronidase alfa) is approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes Crysvita for the treatment of tumor-induced osteomalacia (TIO); DTX401 for the treatment of patients with glycogen storage disease type Ia, or GSDIa; UX007 for the treatment of LC-FAOD and DTX301 for the treatment of ornithine transcarbamylase. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc Key Recent Developments

Apr 01,2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Mar 31,2020: Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing …
Mar 31,2020: Regenxbio teams up with Ultragenyx in gene therapy for rare metabolic disorder
Mar 31,2020: REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ultragenyx Pharmaceutical Inc – Key Facts
Ultragenyx Pharmaceutical Inc – Key Employees
Ultragenyx Pharmaceutical Inc – Key Employee Biographies
Ultragenyx Pharmaceutical Inc – Major Products and Services
Ultragenyx Pharmaceutical Inc – History
Ultragenyx Pharmaceutical Inc – Company Statement
Ultragenyx Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ultragenyx Pharmaceutical Inc – Business Description
Product Category: Crysvita
Overview
Performance
Product Category: Mepsevii
Overview
Performance
Product Category: UX007
Overview
Performance
Geographical Segment: All other
Performance
Geographical Segment: Europe
Performance
Geographical Segment: US
Performance
R&D Overview
Ultragenyx Pharmaceutical Inc – Corporate Strategy
Ultragenyx Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
Ultragenyx Pharmaceutical Inc – Strengths
Ultragenyx Pharmaceutical Inc – Weaknesses
Ultragenyx Pharmaceutical Inc – Opportunities
Ultragenyx Pharmaceutical Inc – Threats
Ultragenyx Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 01, 2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Mar 03, 2020: Ultragenyx announces planned transition of Chief Financial Officer
Feb 13, 2020: Ultragenyx reports fourth quarter and full year 2019 financial results and corporate update
Jan 13, 2020: Ultragenyx reports preliminary 2019 revenue and provides 2020 Crysvita revenue guidance
Nov 05, 2019: Ultragenyx reports third quarter 2019 financial results and corporate update
Aug 01, 2019: Ultragenyx reports second quarter 2019 financial results and corporate update
Jun 17, 2019: Ultragenyx expands leadership team and promotes Erik Harris to chief commercial officer
May 06, 2019: Ultragenyx reports first quarter 2019 financial results and corporate update
Feb 19, 2019: Ultragenyx announces fourth quarter and full year 2018 financial results
Feb 04, 2019: Ultragenyx Pharmaceutical names Shehnaaz Suliman, M.D., to Board of Directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ultragenyx Pharmaceutical Inc, Key Facts
Ultragenyx Pharmaceutical Inc, Key Employees
Ultragenyx Pharmaceutical Inc, Key Employee Biographies
Ultragenyx Pharmaceutical Inc, Major Products and Services
Ultragenyx Pharmaceutical Inc, History
Ultragenyx Pharmaceutical Inc, Subsidiaries
Ultragenyx Pharmaceutical Inc, Key Competitors
Ultragenyx Pharmaceutical Inc, Ratios based on current share price
Ultragenyx Pharmaceutical Inc, Annual Ratios
Ultragenyx Pharmaceutical Inc, Annual Ratios (Cont...1)
Ultragenyx Pharmaceutical Inc, Interim Ratios
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Ultragenyx Pharmaceutical Inc, Performance Chart (2015 - 2019)
Ultragenyx Pharmaceutical Inc, Ratio Charts
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cinemark Holdings Inc (CNK):企業の財務・戦略的SWOT分析
    Cinemark Holdings Inc (CNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • KAZ Minerals PLC:企業の戦略・SWOT・財務情報
    KAZ Minerals PLC - Strategy, SWOT and Corporate Finance Report Summary KAZ Minerals PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Oil Refineries Ltd (ORL):企業の財務・戦略的SWOT分析
    Oil Refineries Ltd (ORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Zhuhai Holdings Investment Group Co Ltd
    Zhuhai Holdings Investment Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Zhuhai Holdings Investment Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Qaf Limited:企業の戦略・SWOT・財務分析
    Qaf Limited - Strategy, SWOT and Corporate Finance Report Summary Qaf Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Macrogen Inc (038290):企業の財務・戦略的SWOT分析
    Macrogen Inc (038290) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sensus USA Inc:企業の戦略的SWOT分析
    Sensus USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • BBB Technologies Inc:企業の製品パイプライン分析
    Summary BBB Technologies Inc (BBB Tech) is a development-stage medical technology company that develops medical devices and applications that facilitate the early diagnosis of metabolic and cardiovascular disorders. It discovers and develops single-drop and mobile integrated diagnostic tools for blo …
  • Prodware SA:企業の戦略・SWOT・財務情報
    Prodware SA - Strategy, SWOT and Corporate Finance Report Summary Prodware SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • CKE Restaurants Holdings Inc.:企業の戦略・SWOT・財務分析
    CKE Restaurants Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary CKE Restaurants Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Vascular Biogenics Ltd (VBLT):企業の財務・戦略的SWOT分析
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …
  • Proengin SA:企業の戦略・SWOT・財務分析
    Proengin SA - Strategy, SWOT and Corporate Finance Report Summary Proengin SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • McWane, Inc.:企業の戦略・SWOT・財務分析
    McWane, Inc. - Strategy, SWOT and Corporate Finance Report Summary McWane, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Verizon Communications Inc.:企業のM&A・事業提携・投資動向
    Verizon Communications Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Verizon Communications Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Relisys Medical Devices Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Relisys Medical Devices Ltd (Relisys), formerly Care Polymed Ltd is a medical device company that develops, manufactures and commercializes catheter products. The company’s products include drug eluting stent systems, bare metal stent systems, PTCA catheters and angiographic catheters. Its a …
  • Tox Free Solutions Limited (TOX):企業の財務・戦略的SWOT分析
    Tox Free Solutions Limited (TOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Nymox Pharmaceutical Corp (NYMX):医療機器:M&Aディール及び事業提携情報
    Summary Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the …
  • Osprey Medical Inc (OSP):企業の財務・戦略的SWOT分析
    Summary Osprey Medical Inc (Osprey Medical) is a medical device company that designs, develops, and manufacturers proprietary devices and monitoring systems. The company offers contrast removal system, which is designed to provide cardiologists with an advanced level of CIN protection in high risk p …
  • The Hartz Mountain Corporation:企業の戦略・SWOT・財務情報
    The Hartz Mountain Corporation - Strategy, SWOT and Corporate Finance Report Summary The Hartz Mountain Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • China Petroleum & Chemical Corporation (Sinopec):戦略・SWOT・企業財務分析
    China Petroleum & Chemical Corporation (Sinopec) - Strategy, SWOT and Corporate Finance Report Summary China Petroleum & Chemical Corporation (Sinopec) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆